Approval · Notice of Compliance 25105 · 2021
REMSIMA: Notice of Compliance 25105
Issued January 28, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25105
- Date
- January 28, 2021
- Company
- Celltrion Healthcare Co Ltd
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Remsina - product monograph update remsins sc - new strength, new route of administraiton, new dosage form, new presentations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REMSIMA | Not yet assigned | — |
| REMSIMA SC | Not yet assigned | — |
Medicinal ingredients
- INFLIXIMAB 100 MG per ML
- INFLIXIMAB 120 MG per SYR
- INFLIXIMAB 120 MG per ML